Kyowa Kirin Presents Data at EORTC-Cutaneous Lymphoma Task Force Meeting Showing Significantly Improved Quality of Life for Patients With Mycosis Fungoides (MF) and Sézary Syndrome (SS) on Mogamulizumab

TOKYO, September 28, 2018 /PRNewswire/ -- First oral presentation of Quality of Life data from the phase III trial (MAVORIC), the largest randomised trial in MF and SS - the two most common types of Cutaneous T Cell Lymphoma[1] Kyowa Hakko Kirin Co., Ltd., (Kyowa Kirin)...

from PR Newswire: //https://ift.tt/2zBkpVg